Insmed (INSM) Tops Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $124.89 -1.11%
Revenue Growth %: +253.1%
Financial Fact:
Net loss attributable to common stockholders: -37.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +253.1%
Financial Fact:
Net loss attributable to common stockholders: -37.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q2 EPS of ($0.80), $0.09 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $58.79 million.
As of June 30, 2022, Insmed had cash and cash equivalents and marketable securities of $564.6 million. The Company\'s total operating expenses for the second quarter of 2022 were $153.5 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Canaan Inc. (CAN) PT Lowered to $2 at BTIG
- BMO Capital Starts Carter's (CRI) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
